Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
Conditions:   Hepatocellular Carcinoma;   Liver Transplantation Intervention:   Drug: Camrelizumab treatment Sponsor:   Third Affiliated Hospital, Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2020 Category: Research Source Type: clinical trials

Study of How Atezolizumab and Bevacizumab Affects the Tumors of Liver Cancer or Lung Cancer With Liver Metastases
Conditions:   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer Metastatic;   Liver Metastases Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab Sponsors:   University Health Network, Toronto;   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

Microwave Ablation Combined With Chemotherapy for Colorectal Liver Metastases : a Multicenter Cohort Study
Conditions:   Colorectal Carcinoma;   Chemotherapy;   Liver Metastases Intervention:   Drug: Chemotherapy Sponsor:   Ping Liang Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial
Condition:   Hepatocellular Carcinoma Interventions:   Drug: Xiang Sha Liu Jun Zi Decoction dry powder;   Drug: XSLJZ Placebo Sponsor:   China Medical University Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

Study of How Atezolizumab and Bevacizumab Affects the Tumors of Liver Cancer or Lung Cancer With Liver Metastases
Conditions:   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer Metastatic;   Liver Metastases Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab Sponsors:   University Health Network, Toronto;   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

Microwave Ablation Combined With Chemotherapy for Colorectal Liver Metastases : a Multicenter Cohort Study
Conditions:   Colorectal Carcinoma;   Chemotherapy;   Liver Metastases Intervention:   Drug: Chemotherapy Sponsor:   Ping Liang Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial
Condition:   Hepatocellular Carcinoma Interventions:   Drug: Xiang Sha Liu Jun Zi Decoction dry powder;   Drug: XSLJZ Placebo Sponsor:   China Medical University Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

Study of How Atezolizumab and Bevacizumab Affects the Tumors of Liver Cancer or Lung Cancer With Liver Metastases
Conditions:   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer Metastatic;   Liver Metastases Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab Sponsors:   University Health Network, Toronto;   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

Microwave Ablation Combined With Chemotherapy for Colorectal Liver Metastases : a Multicenter Cohort Study
Conditions:   Colorectal Carcinoma;   Chemotherapy;   Liver Metastases Intervention:   Drug: Chemotherapy Sponsor:   Ping Liang Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial
Condition:   Hepatocellular Carcinoma Interventions:   Drug: Xiang Sha Liu Jun Zi Decoction dry powder;   Drug: XSLJZ Placebo Sponsor:   China Medical University Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

Microwave Ablation Combined With Chemotherapy for Colorectal Liver Metastases : a Multicenter Cohort Study
Conditions:   Colorectal Carcinoma;   Chemotherapy;   Liver Metastases Intervention:   Drug: Chemotherapy Sponsor:   Ping Liang Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial
Condition:   Hepatocellular Carcinoma Interventions:   Drug: Xiang Sha Liu Jun Zi Decoction dry powder;   Drug: XSLJZ Placebo Sponsor:   China Medical University Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

Study of How Atezolizumab and Bevacizumab Affects the Tumors of Liver Cancer or Lung Cancer With Liver Metastases
Conditions:   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer Metastatic;   Liver Metastases Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab Sponsors:   University Health Network, Toronto;   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 24, 2020 Category: Research Source Type: clinical trials

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Drug: SCT-I10A;   Drug: SCT510;   Drug: Sorafenib 200mg Sponsor:   Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Condition:   Carcinoma, Hepatocellular Interventions:   Drug: Lenvatinib;   Procedure: TACE Sponsor:   Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Drug: SCT-I10A;   Drug: SCT510;   Drug: Sorafenib 200mg Sponsor:   Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Condition:   Carcinoma, Hepatocellular Interventions:   Drug: Lenvatinib;   Procedure: TACE Sponsor:   Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Drug: SCT-I10A;   Drug: SCT510;   Drug: Sorafenib 200mg Sponsor:   Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Condition:   Carcinoma, Hepatocellular Interventions:   Drug: Lenvatinib;   Procedure: TACE Sponsor:   Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Drug: SCT-I10A;   Drug: SCT510;   Drug: Sorafenib 200mg Sponsor:   Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Condition:   Carcinoma, Hepatocellular Interventions:   Drug: Lenvatinib;   Procedure: TACE Sponsor:   Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Drug: SCT-I10A;   Drug: SCT510;   Drug: Sorafenib 200mg Sponsor:   Sinocelltech Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Condition:   Carcinoma, Hepatocellular Interventions:   Drug: Lenvatinib;   Procedure: TACE Sponsor:   Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials

Cytokine Change in Hepatocellular Carcinoma Treated by Thermal Ablation
Condition:   Hepatocellular Carcinoma Intervention:   Device: Radiofrequency ablation or microwave ablation Sponsors:   Chinese University of Hong Kong;   The Hong Kong Society of Gastroenterology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2020 Category: Research Source Type: clinical trials

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Device: Radiofrequency ablation;   Drug: Trance-arterial chemoembolization;   Procedure: Liver resection;   Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection;   Drug: Percutaneous ethanol injection;   Drug: Systemic chemotherapy;   Drug: Sor afenib;   Dietary Supplement: Viscum;   Drug: Symptomatic treatment Sponsor:   Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment
Condition:   Hepatocellular Carcinoma Intervention:   Device: Ultrasound ELastography Sponsor:   Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Device: Radiofrequency ablation;   Drug: Trance-arterial chemoembolization;   Procedure: Liver resection;   Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection;   Drug: Percutaneous ethanol injection;   Drug: Systemic chemotherapy;   Drug: Sor afenib;   Dietary Supplement: Viscum;   Drug: Symptomatic treatment Sponsor:   Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment
Condition:   Hepatocellular Carcinoma Intervention:   Device: Ultrasound ELastography Sponsor:   Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Device: Radiofrequency ablation;   Drug: Trance-arterial chemoembolization;   Procedure: Liver resection;   Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection;   Drug: Percutaneous ethanol injection;   Drug: Systemic chemotherapy;   Drug: Sor afenib;   Dietary Supplement: Viscum;   Drug: Symptomatic treatment Sponsor:   Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment
Condition:   Hepatocellular Carcinoma Intervention:   Device: Ultrasound ELastography Sponsor:   Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Device: Radiofrequency ablation;   Drug: Trance-arterial chemoembolization;   Procedure: Liver resection;   Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection;   Drug: Percutaneous ethanol injection;   Drug: Systemic chemotherapy;   Drug: Sor afenib;   Dietary Supplement: Viscum;   Drug: Symptomatic treatment Sponsor:   Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment
Condition:   Hepatocellular Carcinoma Intervention:   Device: Ultrasound ELastography Sponsor:   Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Device: Radiofrequency ablation;   Drug: Trance-arterial chemoembolization;   Procedure: Liver resection;   Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection;   Drug: Percutaneous ethanol injection;   Drug: Systemic chemotherapy;   Drug: Sor afenib;   Dietary Supplement: Viscum;   Drug: Symptomatic treatment Sponsor:   Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment
Condition:   Hepatocellular Carcinoma Intervention:   Device: Ultrasound ELastography Sponsor:   Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Device: Radiofrequency ablation;   Drug: Trance-arterial chemoembolization;   Procedure: Liver resection;   Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection;   Drug: Percutaneous ethanol injection;   Drug: Systemic chemotherapy;   Drug: Sor afenib;   Dietary Supplement: Viscum;   Drug: Symptomatic treatment Sponsor:   Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment
Condition:   Hepatocellular Carcinoma Intervention:   Device: Ultrasound ELastography Sponsor:   Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Device: Radiofrequency ablation;   Drug: Trance-arterial chemoembolization;   Procedure: Liver resection;   Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection;   Drug: Percutaneous ethanol injection;   Drug: Systemic chemotherapy;   Drug: Sor afenib;   Dietary Supplement: Viscum;   Drug: Symptomatic treatment Sponsor:   Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment
Condition:   Hepatocellular Carcinoma Intervention:   Device: Ultrasound ELastography Sponsor:   Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
Condition:   Hepatocellular Carcinoma Interventions:   Device: Radiofrequency ablation;   Drug: Trance-arterial chemoembolization;   Procedure: Liver resection;   Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection;   Drug: Percutaneous ethanol injection;   Drug: Systemic chemotherapy;   Drug: Sor afenib;   Dietary Supplement: Viscum;   Drug: Symptomatic treatment Sponsor:   Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2020 Category: Research Source Type: clinical trials